Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S11, June 2016

Initial Comparisons of Three Apheresis Platforms for Supporting the Collection of CD3+ Cells for CAR-T Production

      Introduction: Collection by apheresis is often overlooked in the cell therapy manufacturing process. With the decommissioning of the Cobe Spectra, there is a need to evaluate whether replacement apheresis platforms will have any negative impacts. This pilot study compared the Cobe Spectra with the Spectra Optia Mononuclear Cell (MNC) and the more recent cMNC programmes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect